Abstract:The cannabinoid receptor 2 (CB2) plays an important role in the immune system. Although a few of GPCRs crystallographic structures have been reported, it is still challenging to obtain functional transmembrane proteins and high resolution X-ray crystal structures, such as for the CB2 receptor. In the present work, we used 10 reported crystal structures of GPCRs which had high sequence identities with CB2 to construct homology-based comparative CB2 models. We applied these 10 models to perform a prescreen by using a training set consisting of 20 CB2 active compounds and 980 compounds randomly selected from the National Cancer Institute (NCI) database. We then utilized the known 170 cannabinoid receptor 1 (CB1) or CB2 selective compounds for further validation. Based on the docking results, we selected one CB2 model (constructed by β1AR) that was most consistent with the known experimental data, revealing that the defined binding pocket in our CB2 model was well-correlated with the training and testing data studies. Importantly, we identified a potential allosteric binding pocket adjacent to the orthosteric ligand-binding site, which is similar to the reported allosteric pocket for sodium ion Na(+) in the A2AAR and the δ-opioid receptor. Our studies in correlation of our data with others suggested that sodium may reduce the binding affinities of endogenous agonists or its analogs to CB2. We performed a series of docking studies to compare the important residues in the binding pockets of CB2 with CB1, including antagonist, agonist, and our CB2 neutral compound (neutral antagonist) XIE35-1001. Then, we carried out 50 ns molecular dynamics (MD) simulations for the CB2 docked with SR144528 and CP55940, respectively. We found that the conformational changes of CB2 upon antagonist/agonist binding were congruent with recent reports of those for other GPCRs. Based on these results, we further examined one known residue, Val113(3.32), and predicted two new residues, Phe183 in ECL2 and Phe281(7.35), that were important for SR144528 and CP55940 binding to CB2. We then performed site-directed mutation experimental study for these residues and validated the predictions by radiometric binding affinity assay.

Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.

A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening

Design, Syntheses, and Characterization of Piperazine Based Chemokine Receptor CCR5 Antagonists As Anti Prostate Cancer Agents.

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

On the Value of Homology Models for Virtual Screening: Discovering hCXCR3 Antagonists by Pharmacophore-Based and Structure-Based Approaches.

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly

3D-QSAR, molecular docking and molecular dynamics studies of a series of RORγt inhibitors.

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives As CCR5 Antagonists

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

Molecular Modeling and Site-Directed Mutagenesis of Ccr5 Reveal Residues Critical for Chemokine Binding and Signal Transduction

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Design, Synthesis, and Biological Evaluation of Novel 2-Methylpiperazine Derivatives As Potent CCR5 Antagonists.

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Structure-Based Development of Antagonists for Chemokine Receptor CXCR4